Japan's Ministry of Health, Labour and Welfare has approved Sanofi's (EURONEXT: SAN, NASDAQ: SNY) subcutaneous formulation of Sarclisa (isatuximab) for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

FDA